A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• N.M. Hahn, W.M. Stadler, R.T. Zon, D. Waterhouse, J. Picus, S. Nattam, C.S. Johnson, S.M. Perkins, C.J. Sweeney. A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC); Hoosier Oncology Group GU04-75. Accepted as an oral presentation at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL. J Clin Oncol 27:15s, 2009 (suppl; abstr 5018)
• N. M. Hahn, W. M. Stadler, R. Zon, D. M. Waterhouse, J. Picus, S. R. Nattam, C. S. Johnson, S. M. Perkins, M. J. Waddell, C. Sweeney. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). Accepted as a poster discussion at the ASCO annual meeting June 4-8, 2010, Chicago IL. J Clin Oncol 28:15s, 2010 (suppl; abstr 4541)

Manuscripts/Articles:

• Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ. Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU04-75. J Clin Oncol. 2011 Mar 21. [Epub ahead of print] PMID: 21422406. See abstract.